NA

Inari Medical IncNASDAQ NARI Stock Report

Last reporting period 30 Jun, 2024

Updated 19 Sep, 2024

Last price

Market cap $B

2.57

Small

Exchange

XNAS - Nasdaq

NARI Stock Analysis

NA

Uncovered

Inari Medical Inc is uncovered by Eyestock quantitative analysis.

Rating

To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.

28/100

Low score

Market cap $B

2.57

Dividend yield

Shares outstanding

54.314 B

Inari Medical, Inc. operates as a medical device company. The company is headquartered in Irvine, California and currently employs 1,100 full-time employees. The company went IPO on 2020-05-22. The firm operates through the development and commercialization of invasive mechanical thrombectomy devices to treat thromboembolism in the venous system. Its product offerings consist of two minimally invasive, catheter-based mechanical thrombectomy systems, which are for venous system and the treatment of the two distinct manifestations of venous thromboembolism (VTE), deep vein thrombosis (DVT), and pulmonary embolism (PE). The Company’s products include ClotTriever System, FlowTriever System, FlowSaver, FlowStasis and FlowTriever 2. The ClotTriever system is a mechanical thrombectomy system designed to core, capture and remove large clots from large vessels and is used to treat DVT and its components include ClotTriever Catheter and ClotTriever Sheath. The Company’s FlowTriever is a large bore catheter-based aspiration and mechanical thrombectomy system designed to remove large clots from large vessels to treat PE.

View Section: Eyestock Rating